Literature DB >> 2984238

Isolation and structural identification of 1,25-dihydroxyvitamin D3 produced by cultured alveolar macrophages in sarcoidosis.

J S Adams, F R Singer, M A Gacad, O P Sharma, M J Hayes, P Vouros, M F Holick.   

Abstract

Hypercalcemia and hypercalciuria in sarcoidosis are thought to result from the endogenous overproduction of an active vitamin D metabolite. We employed primary cultures of pulmonary alveolar macrophages from two patients with biopsy-proven pulmonary sarcoidosis and a recent or current clinical abnormality in calcium metabolism to synthesize in vitro a 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3]-like metabolite from 25-hydroxyvitamin D3 (25OHD3). The macrophage metabolite cochromatographed with [3H]1,25-(OH)2D3 on normal phase and reverse phase high performance liquid chromatography and was bound with high affinity by the chick intestinal receptor for 1,25-(OH)2D3. On UV spectroscopy, the metabolite possessed the carbon-5,7,10 (19) cis-triene chromophore characteristic of a vitamin D sterol. Electron impact mass spectrometry of trimethylsilyl ether derivatives of the metabolite revealed a mass fragmentation pattern similar to that of the trimethylsilyl ether derivative of authentic 1,25-(OH)2D3. The incubation of cultured macrophages from two patients with idiopathic pulmonary fibrosis and two with scleroderma with [3H]25OHD3 did not result in production of a metabolite with the chromatographic identity of 1,25-(OH)2D3. These data indicate that the metabolite of 25OHD3 synthesized by sarcoid macrophages in vitro is 1,25-(OH)2D3 and that the macrophage is a synthetic source of the sterol metabolite in sarcoidosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2984238     DOI: 10.1210/jcem-60-5-960

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  48 in total

1.  Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density.

Authors:  M T Abreu; V Kantorovich; E A Vasiliauskas; U Gruntmanis; R Matuk; K Daigle; S Chen; D Zehnder; Y-C Lin; H Yang; M Hewison; J S Adams
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

2.  Hypergammaglobulinemia, normal serum albumin and hypercalcaemia: a case of systemic sarcoidosis with initial diagnostic confusion.

Authors:  Sathiji Nageshwaran; Kalpita Majumdar; Sabina Russell
Journal:  BMJ Case Rep       Date:  2012-06-21

3.  Hypercalcaemia and sarcoidosis in infancy.

Authors:  S J Stanworth; C T Kennedy; P A Chetcuti; F Carswell
Journal:  J R Soc Med       Date:  1992-03       Impact factor: 5.344

Review 4.  Genetics of sarcoidosis: candidate genes and genome scans.

Authors:  Michael C Iannuzzi; Benjamin A Rybicki
Journal:  Proc Am Thorac Soc       Date:  2007-01

5.  CYP27B1 null mice with LacZreporter gene display no 25-hydroxyvitamin D3-1alpha-hydroxylase promoter activity in the skin.

Authors:  Janeen L Vanhooke; Jean M Prahl; Christine Kimmel-Jehan; Monica Mendelsohn; Eric W Danielson; Kevin D Healy; Hector F DeLuca
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-21       Impact factor: 11.205

Review 6.  Clinical impact of bone and calcium metabolism changes in sarcoidosis.

Authors:  G Rizzato
Journal:  Thorax       Date:  1998-05       Impact factor: 9.139

Review 7.  Vitamin D-endocrine system.

Authors:  N H Bell
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

8.  Stat1-vitamin D receptor interactions antagonize 1,25-dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription.

Authors:  Marcos Vidal; Chilakamarti V Ramana; Adriana S Dusso
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

9.  Vitamin D metabolism and action in human bone marrow stromal cells.

Authors:  Shuanhu Zhou; Meryl S LeBoff; Julie Glowacki
Journal:  Endocrinology       Date:  2009-12-04       Impact factor: 4.736

Review 10.  Hypercalcaemia of malignancy.

Authors:  P J Kelly; J A Eisman
Journal:  Cancer Metastasis Rev       Date:  1989-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.